Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.London-based multinational pharmaceutical company Hikma Pharmaceuticals has bought minority interest in China-based Hubei Haosun Pharmaceutical, a supplier of active pharmaceutical ingredients' (API), for $5m.
Subscribe to our email newsletter
With this acquisition, Hikma intends to strengthen its API sourcing and R&D capabilities in key product areas.
The deal allows Hikma to get license to Haosun’s APIs particularly targeting oncology area.
Haosun is engaged in organic synthesis, fermentation production, process development and manufacturing.